| 2024-06-10 |
详情>>
内部人交易：
Sun Kevin M股份减少445.00股
|
| 2024-05-15 |
详情>>
股本变动：
变动后总股本3496.30万股
变动原因 ▼▲
- 原因：
- From December 31, 2023 to March 31, 2024
Issuance of common stock from Employee Stock Purchase Plan
Issuance of common stock under stock plans, net of shares withheld for employee taxes
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.58美元,归母净利润-2001万美元,同比去年增长36.01%
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-3.09美元,归母净利润-1.01亿美元,同比去年增长13.54%
|
| 2024-02-29 |
财报披露：
美东时间 2024-02-29 盘后发布财报
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.55美元,归母净利润-8179.7万美元,同比去年增长7.53%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-2.01美元,归母净利润-6263.3万美元,同比去年增长-4.93%
|
| 2023-05-04 |
详情>>
业绩披露：
2023年一季报每股收益-1.02美元,归母净利润-3127万美元,同比去年增长-3.86%
|
| 2023-04-11 |
股东大会：
将于2023-05-31召开股东大会
会议内容 ▼▲
- 1.To elect one (1) Class III director to serve a three-year term expiring in 2026;
2.To approve a proposed amendment to the Company’s Amended and Restated Certificate of Incorporation to increase from 50,000,000 shares to 100,000,000 shares the aggregate number of shares of common stock authorized to be issued;
3.To approve a proposed amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation;
4.To approve an amendment to the DermTech, Inc. 2020 Equity Incentive Plan to modify the plan’s evergreen provision;
5.To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
6.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement;
7.To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.
|
| 2023-03-02 |
详情>>
业绩披露：
2022年年报每股收益-3.88美元,归母净利润-1.17亿美元,同比去年增长-48.95%
|
| 2023-03-02 |
详情>>
业绩披露：
2021年年报每股收益-2.71美元,归母净利润-7833.5万美元,同比去年增长-114.75%
|
| 2022-11-04 |
复牌提示：
2022-11-04 09:34:44 停牌，复牌日期 2022-11-04 09:39:44
|
| 2022-11-03 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.95美元,归母净利润-8846万美元,同比去年增长-69.2%
|
| 2022-08-08 |
详情>>
业绩披露：
2022年中报每股收益-2美元,归母净利润-5968.8万美元,同比去年增长-85.54%
|
| 2022-05-03 |
详情>>
业绩披露：
2022年一季报每股收益-1.01美元,归母净利润-3010.8万美元,同比去年增长-99.81%
|
| 2022-04-14 |
股东大会：
将于2022-05-26召开股东大会
会议内容 ▼▲
- 1.To elect two (2) Class I directors to serve three-year terms expiring in 2025;
2.To ratify the selection of KPMG LLP as the independent registered public accounting firm of DermTech, Inc. for the fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of our named executive officers;
5.To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.
|
| 2022-03-10 |
详情>>
业绩披露：
2020年年报每股收益-2.15美元,归母净利润-3647.7万美元,同比去年增长-81.21%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-16 |
股东大会：
将于2021-05-26召开股东大会
会议内容 ▼▲
- 1.To elect two (2) Class II directors to serve three-year terms expiring in 2024;
2.To ratify the selection of KPMG LLP as the independent registered public accounting firm of DermTech, Inc. for the fiscal year ending December 31, 2021;
3.To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.
|
| 2020-04-29 |
股东大会：
将于2020-05-21召开股东大会
会议内容 ▼▲
- 1.To elect one (1) director to serve a three-year term expiring in 2023;
2.To approve the DermTech, Inc. 2020 Equity Incentive Plan;
3.To approve the DermTech, Inc. 2020 Employee Stock Purchase Plan;
4.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying Series B1 and Series B2 Convertible Preferred Stock issued by us pursuant to the terms of the Securities Purchase Agreement dated February 28, 2020 between DermTech, Inc. and the purchasers identified therein, in an amount equal to or in excess of 20% of our common stock then outstanding;
5.To amend the certificate of incorporation of DermTech, Inc. to add an exclusive federal forum clause;
6.To ratify the selection of KPMG LLP as the independent registered public accounting firm of DermTech, Inc. for the fiscal year ending December 31, 2020;
7.To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.
|
| 2019-08-30 |
详情>>
拆分方案：
每2.0000合并分成1.0000股
|
| 2019-02-26 |
股东大会：
将于2019-03-21召开股东大会
会议内容 ▼▲
- 1.a proposal to amend (the “Extension Amendment”) CNAC’s Amended and Restated Memorandum and Articles of Association (the “Amended and Restated Memorandum and Articles of Association”) to extend the date by which CNAC has to consummate a business combination (the “Extension”) for an additional six months, from March 23, 2019 to September 23, 2019 (the “Extended Date”) by amending the Amended and Restated Memorandum and Articles of Association to delete the existing Regulation 23.2 of the Amended and Restated Articles of Association and replacing it with the new Regulation 23.2 in the form set forth in Annex A of the proxy statement;
2.a proposal to re-elect (the “Director Proposal”) two directors to the Company’s board of directors (the “Board”), with each such director to serve until the second annual general meeting of shareholders following this special meeting or until his successor is elected and qualified;
3.a proposal to ratify the selection by CNAC’s Audit Committee of Marcum LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2019 (the “Auditor Proposal”).
|